MUSC Health - Bluffton Medical Pavilion

MUSC Health Bluffton Medical Pavilion is a new medical office building serving Beaufort County communities. This location includes the MUSC Health Breast Care Center, led by Dr. Christie Hilton, a recognized expert in breast health and breast oncology. MUSC Health – Bluffton will soon be active on the following clinical trials.

MUSC Health Bluffton Medical Pavilion
700 Buckwalter Towne Boulevard
Bluffton, SC 29910
843-792-2300

Contact
Lauren Oliver, RN
Research Coordinator
olivelau@musc.edu

Breast

• A012103: Pembrolizumab vs. Observation in People with Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab (PENDING)
  To evaluate whether observation results in a non-inferior RFS compared to adjuvant pembrolizumab in early-stage TNBC patients who achieve a pCR after neoadjuvant chemotherapy with pembrolizumab.
• A012303: ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade
  This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab.
• BR009: Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression plus Hormonal Therapy in Premenopausal ER-Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning, OFSET Trial (PENDING)
  This phase III trial compares the addition of chemotherapy to usual treatment (ovarian function suppression plus hormonal therapy) to usual treatment alone in treating premenopausal estrogen receptor (ER)-positive/HER2-negative breast cancer patients who are at high risk of their cancer returning.
• NRG-CC015: Harnessing E-mindfulness Approaches for Living After Breast Cancer - HEAL ABC
  This clinical trial compares the effect of a live instructor led version of the mindfulness meditation-based intervention, Mindful Awareness Practices (MAPs) and MAPs application (App)-based, self-directed version to guided audio meditation alone on mental health and well-being in younger patients with stage 0-III breast cancer.
• S2206: Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer (PENDING)
  To compare breast cancer event-free survival between participants randomized to standard of care neoadjuvant chemotherapy alone versus standard of care neoadjuvant chemotherapy concurrent with durvalumab.